Protagonist Therapeutics, Inc - PTGX
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Mar 27, 2026 | SCHEDULE 13G/A | The Vanguard Group | 0.0% | 0 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | RTW Investments, LP | 8.1% | 5,059,053 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Roderick Wong | 8.1% | 5,059,053 | View |
| Feb 10, 2026 | SCHEDULE 13G | Wellington Management Group LLP | 5.1% | 3,171,423 | View |
| Feb 10, 2026 | SCHEDULE 13G | Wellington Group Holdings LLP | 5.1% | 3,171,423 | View |
| Feb 10, 2026 | SCHEDULE 13G | Wellington Investment Advisors Holdings LLP | 5.1% | 3,171,423 | View |
| Feb 06, 2026 | SCHEDULE 13G/A | Farallon Capital Partners, L.P. | 0.5% | 283,062 | View |
| Feb 06, 2026 | SCHEDULE 13G/A | Farallon Capital Institutional Partners, L.P. | 0.5% | 290,850 | View |
| Feb 06, 2026 | SCHEDULE 13G/A | Farallon Capital Institutional Partners II, L.P. | 0.1% | 91,421 | View |
| Feb 06, 2026 | SCHEDULE 13G/A | Farallon Capital Institutional Partners III, L.P. | 0.1% | 39,417 | View |
| Feb 06, 2026 | SCHEDULE 13G/A | Four Crossings Institutional Partners V, L.P. | 0.1% | 53,343 | View |
| Feb 06, 2026 | SCHEDULE 13G/A | Farallon Capital Offshore Investors II, L.P. | 0.9% | 565,080 | View |
| Feb 06, 2026 | SCHEDULE 13G/A | Farallon Capital (AM) Investors, L.P. | 0.1% | 36,181 | View |
| Feb 06, 2026 | SCHEDULE 13G/A | Farallon Capital F5 Master I, L.P. | 0.2% | 121,094 | View |
| Feb 06, 2026 | SCHEDULE 13G/A | Farallon Healthcare Partners Master, L.P. | 7.6% | 4,767,564 | View |
| Feb 06, 2026 | SCHEDULE 13G/A | Farallon Partners, L.L.C. | 9.8% | 6,126,919 | View |
| Feb 06, 2026 | SCHEDULE 13G/A | Farallon Institutional (GP) V, L.L.C. | 0.1% | 53,343 | View |
| Feb 06, 2026 | SCHEDULE 13G/A | Farallon F5 (GP), L.L.C. | 0.2% | 121,094 | View |
| Feb 06, 2026 | SCHEDULE 13G/A | Farallon Healthcare Partners (GP), L.L.C. | 7.6% | 4,767,564 | View |
| Feb 06, 2026 | SCHEDULE 13G/A | Dapice Joshua J. | 9.99% | 6,248,013 | View |
| Feb 06, 2026 | SCHEDULE 13G/A | Dreyfuss, Philip D. | 9.99% | 6,248,013 | View |
| Feb 06, 2026 | SCHEDULE 13G/A | Dunn Hannah E. | 9.99% | 6,248,013 | View |
| Feb 06, 2026 | SCHEDULE 13G/A | Fried, Richard B | 0.0% | 0 | View |
| Feb 06, 2026 | SCHEDULE 13G/A | Gehani, Varun N. | 9.99% | 6,248,013 | View |
| Feb 06, 2026 | SCHEDULE 13G/A | Giauque, Nicolas | 9.99% | 6,248,013 | View |
| Feb 06, 2026 | SCHEDULE 13G/A | Husen, Avner A. | 9.99% | 6,248,013 | View |
| Feb 06, 2026 | SCHEDULE 13G/A | Kim, David T. | 9.99% | 6,248,013 | View |
| Feb 06, 2026 | SCHEDULE 13G/A | Linn, Michael G. | 9.99% | 6,248,013 | View |
| Feb 06, 2026 | SCHEDULE 13G/A | Luo Patrick (Cheng) | 9.99% | 6,248,013 | View |
| Feb 06, 2026 | SCHEDULE 13G/A | Patel, Rajiv A. | 0.0% | 0 | View |
| Feb 06, 2026 | SCHEDULE 13G/A | Roberts, Jr., Thomas G. | 9.99% | 6,248,013 | View |
| Feb 06, 2026 | SCHEDULE 13G/A | Saito Edric C. | 9.99% | 6,248,013 | View |
| Feb 06, 2026 | SCHEDULE 13G/A | Seybold, William | 0.0% | 0 | View |
| Feb 06, 2026 | SCHEDULE 13G/A | Short Daniel S. | 9.99% | 6,248,013 | View |
| Feb 06, 2026 | SCHEDULE 13G/A | Spokes, Andrew J. M. | 9.99% | 6,248,013 | View |
| Feb 06, 2026 | SCHEDULE 13G/A | Warren, John R. | 9.99% | 6,248,013 | View |
| Feb 06, 2026 | SCHEDULE 13G/A | Wehrly, Mark C. | 9.99% | 6,248,013 | View |
| Jan 30, 2026 | SCHEDULE 13G/A | The Vanguard Group | 8.65% | 5,413,690 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | BIOTECHNOLOGY VALUE FUND L P | 2.1% | 1,323,333 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | BVF I GP LLC | 2.1% | 1,323,333 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | BIOTECHNOLOGY VALUE FUND II LP | 1.7% | 1,045,774 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | BVF II GP LLC | 1.7% | 1,045,774 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Biotechnology Value Trading Fund OS LP | 0.2% | 140,917 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | BVF Partners OS Ltd. | 0.2% | 140,917 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | BVF GP HOLDINGS LLC | 3.8% | 2,369,107 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | BVF PARTNERS L P/IL | 4.1% | 2,560,916 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | BVF INC/IL | 4.1% | 2,560,916 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | LAMPERT MARK N | 4.1% | 2,560,916 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Deep Track Capital, LP | 2.76% | 1,715,691 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Deep Track Biotechnology Master Fund, Ltd. | 2.76% | 1,715,691 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | David Kroin | 2.76% | 1,715,691 | View |
| Oct 17, 2025 | SCHEDULE 13G/A | BlackRock, Inc. | 13.8% | 8,575,669 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.